Saturday 17 October 2026 Export AYTU’s income statement to Excel — free account

Aytu BioPharma, Inc.

AYTU Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.

2.04 0.03 +1.49%

Follow AYTU

Alert me

Market cap: $21.8M
P/E: 0.0×
Fwd P/E: −9.2×
Dividend yield: —
F-score: 3/9
Altman Z: −4.04
Beneish M: −3.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	0.00	0.00	0.00	0.00	+8 more quarters Free account
P/S ratio Full definition →	0.46	0.51	0.42	0.28
P/FCF ratio Full definition →	8.19	18.22	0.00	0.00
P/Operating CF Full definition →	6.01	(6.86)	7.10	(28.72)
P/B ratio Full definition →	0.75	0.82	1.84	0.77
Price to Tangible BV Full definition →	0.00	0.00	0.00	0.00
EV/Sales Full definition →	0.30	0.42	0.27	0.19
EV/EBITDA Full definition →	0.00	0.00	0.00	0.00
EV/Operating CF Full definition →	5.25	14.18	(28.57)	(9.01)
EV/FCF Full definition →	5.32	15.11	(30.74)	(13.29)
Quick Ratio Full definition →	0.90	0.85	0.93	1.00
Current Ratio Full definition →	1.13	1.12	1.16	1.23
Net Debt/EBITDA Full definition →	(24.94)	1.68	8.61	8.11
Debt/Assets Full definition →	16.22%	19.53%	17.16%	21.74%
Debt/Equity Full definition →	0.48	0.62	1.47	1.17
Asset Turnover Full definition →	0.50	0.48	0.53	0.53
Operating CF/Net income Full definition →	(293.73)	0.74	(0.35)	(0.31)
Capex/Depreciation Full definition →	(0.01)	0.00	(0.02)	0.00
Interest Coverage Full definition →	(2.03)	(9.32)	(3.52)	(2.91)
Research and Development Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →	64.73%	87.84%	72.98%	73.78%
Intangible Assets out of Total Assets Full definition →	0.39	0.38	0.36	0.33
Share Based Compensation of Revenue Full definition →	0.91%	1.19%	1.87%	0.82%
Graham Net Nets Full definition →	(0.30)	(0.32)	(1.21)	(1.17)
Graham Number Full definition →	0.00	0.00	0.00	0.00
Earnings Yield Full definition →	(63.72%)	(157.14%)	(119.62%)	(102.66%)
Free Cash Flow Yield Full definition →	12.21%	5.49%	(2.12%)	(5.21%)
Revenue per Share Full definition →	1.31	1.18	1.51	1.47
Operating CF per Share Full definition →	0.36	(0.40)	0.37	(0.07)
Capex per Share Full definition →	0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →	0.36	(0.40)	0.36	(0.07)
Cash per Share Full definition →	2.14	2.54	2.99	3.46
Shareholders Equity per Share Full definition →	2.86	3.34	1.42	2.45
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	2.86	3.34	1.42	2.45
Free Cash Flow Full definition →	4.39	(4.18)	3.66	(0.62)
Working Capital Full definition →	7.10	7.35	10.68	15.12
Capital Expenditures Full definition →	(0.01)	0.00	(0.02)	—
Net Current Asset Value Full definition →	(7.97)	(9.22)	(31.56)	(20.71)
EV/EBIT Full definition →	0.00	0.00	0.00	0.00
Capex to Sales Full definition →	0.00	0.00	0.00	0.00
Price to Operating Income Full definition →	0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →	26.97	30.16	28.16	28.19
Average Payables Full definition →	10.94	12.63	12.98	12.93
Average Inventory Full definition →	9.15	9.26	9.87	10.92
Average Assets Full definition →	114.59	117.95	119.11	120.41
Average Common Equity Full definition →	27.12	35.02	22.48	26.50

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026

Stockrow Weekly